newsfilter
← Latest News
Business Wire·

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Company to provide a comprehensive Phase 1 clinical update for prulacabtagene leucel (prula-cel, formerly ADI-001), featuring data from 22 patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) with